|
脑膜炎球菌荚膜W组多糖21/180
|
EA
|
21/180
|
4502
|
1-4/12周
|
|
流感抗原B/普吉岛/3073/2013[B山形谱系]21/136
|
EA
|
21/136
|
4081
|
1-4/12周
|
|
流感病毒传染性BX-93A[B-维多利亚谱系]21/156
|
EA
|
21/156
|
咨询
|
1-4/12周
|
|
流感病毒传染性X-359[H3N2]21/148
|
EA
|
21/148
|
咨询
|
1-4/12周
|
|
流感病毒传染性BX-93B[B-维多利亚谱系]21/158
|
EA
|
21/158
|
咨询
|
1-4/12周
|
|
流感病毒传染性X-359A[H3N2]21/150
|
EA
|
21/150
|
咨询
|
1-4/12周
|
|
9号国际标准因子VIII浓缩物,人21/142
|
EA
|
21/142
|
4988
|
1-4/12周
|
|
流感抗-A/柬埔寨/e0826360/2020-Like[H3N2]HA血清21/118
|
EA
|
21/118
|
4081
|
1-4/12周
|
|
传染性B型流感病毒/香港/574/2019[B-维多利亚系]21/124
|
EA
|
21/124
|
咨询
|
1-4/12周
|
|
流感病毒传染性SAN-004A[H3N2]21/130
|
EA
|
21/130
|
咨询
|
1-4/12周
|
|
流感抗原A/塔斯马尼亚/503/2020[IVR-221][H3N2]21/116
|
EA
|
21/116
|
4081
|
1-4/12周
|
|
流感抗A/Victoria/2570/2019样[H1N1]HA血清21/120
|
EA
|
21/120
|
4081
|
1-4/12周
|
|
流感病毒传染性X-357A[H3N2]21/122
|
EA
|
21/122
|
咨询
|
1-4/12周
|
|
流感抗原A/柬埔寨/e0826360/2020[IVR-224][H3N2]21/100
|
EA
|
21/100
|
4081
|
1-4/12周
|
|
甲型流感病毒/新加坡/INFIMH-16-0019/2016[H3N2]20/322
|
EA
|
20/322
|
咨询
|
1-4/12周
|
|
拉沙病毒RNA21/110工作试剂
|
EA
|
21/110
|
4502
|
1-4/12周
|
|
第2批WHO国际脑膜炎球菌荚膜C组多糖标准20/314
|
EA
|
20/314
|
4988
|
1-4/12周
|
|
流感病毒传染性IVR-221[H3N2]20/318
|
EA
|
20/318
|
咨询
|
1-4/12周
|
|
第1批WHO拉沙病毒RNA国际标准21/112
|
EA
|
21/112
|
4988
|
1-4/12周
|
|
XIII因子血浆的第2批国际标准,人源20/292
|
EA
|
20/292
|
4988
|
1-4/12周
|
